ChromaDex Stock Price, News & Analysis (NASDAQ:CDXC)

$6.24 -0.30 (-4.59 %)
(As of 12/15/2017 01:13 AM ET)
Previous Close$6.54
Today's Range$6.10 - $6.65
52-Week Range$2.26 - $7.24
Volume439,200 shs
Average Volume315,579 shs
Market Capitalization$313.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.38

About ChromaDex (NASDAQ:CDXC)

ChromaDex logoChromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDXC
CUSIPN/A
Phone949-419-0288

Debt

Debt-to-Equity Ratio0.01%
Current Ratio5.03%
Quick Ratio4.12%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.81 million
Price / Sales11.22
Cash FlowN/A
Price / CashN/A
Book Value$0.26 per share
Price / Book24.00

Profitability

Trailing EPS($0.14)
Net Income$-2,920,000.00
Net Margins-21.89%
Return on Equity-47.30%
Return on Assets-32.25%

Miscellaneous

Employees93
Outstanding Shares48,190,000

ChromaDex (NASDAQ:CDXC) Frequently Asked Questions

What is ChromaDex's stock symbol?

ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."

How were ChromaDex's earnings last quarter?

ChromaDex Corporation (NASDAQ:CDXC) posted its quarterly earnings results on Thursday, August, 11th. The company reported $0.01 earnings per share for the quarter. The company had revenue of $8.80 million for the quarter, compared to the consensus estimate of $6.10 million. ChromaDex had a negative return on equity of 47.30% and a negative net margin of 21.89%. View ChromaDex's Earnings History.

When will ChromaDex make its next earnings announcement?

ChromaDex is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for ChromaDex.

Where is ChromaDex's stock going? Where will ChromaDex's stock price be in 2017?

3 brokerages have issued 1 year price objectives for ChromaDex's stock. Their predictions range from $6.00 to $8.00. On average, they anticipate ChromaDex's stock price to reach $7.00 in the next twelve months. View Analyst Ratings for ChromaDex.

What are Wall Street analysts saying about ChromaDex stock?

Here are some recent quotes from research analysts about ChromaDex stock:

  • 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (11/29/2017)
  • 2. HC Wainwright analysts commented, "We note that the company’s revenues came in at $5.3M vs. our original forecast of $8M, while a net loss of $2.7M or $0.07 per share was also recorded vs. our projection for a positive EPS of $0.04. While R&D spending in the quarter was roughly in-line with our estimate at $728K vs. $700K, we note that COGS were slightly worse than our estimate, coming in at 57% vs. our projection of 49%. Given what we see as the current status of ChromaDex’s ingredients business, we have revised our 2017 revenue number to $24.3M, while we now project a net loss per share for 2017 of $0.14 vs. our prior forecast for EPS of $0.16 for the year." (8/11/2017)

Who are some of ChromaDex's key competitors?

Who are ChromaDex's key executives?

ChromaDex's management team includes the folowing people:

  • Stephen Allen, Independent Chairman of the Board (Age 67)
  • Robert N. Fried, President, Independent Director, Chief Strategy Officer (Age 57)
  • Frank L. Jaksch Jr., Chief Executive Officer, Independent Director (Age 48)
  • Kevin M. Farr CPA, Chief Financial Officer, Secretary, Principal Accounting Officer and Principal Financial Officer (Age 59)
  • Troy Rhonemus, Chief Operating Officer (Age 44)
  • Thomas C. Varvaro, Senior Vice President - Finance (Age 47)
  • Andrew Johnson, Director of Investor Relations, IR Contact Officer
  • Tony Lau, Director
  • Steven D. Rubin Esq. J.D., Director (Age 56)
  • Wendy Yu, Director

Who owns ChromaDex stock?

ChromaDex's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tieton Capital Management LLC (1.28%), Granite Investment Partners LLC (0.54%), Susquehanna International Group LLP (0.07%), Segall Bryant & Hamill LLC (0.06%) and Thompson Davis & CO. Inc. (0.06%). Company insiders that own ChromaDex stock include Frank L Jaksch Jr, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer, Stephen R Allen and Troy Allen Rhonemus. View Institutional Ownership Trends for ChromaDex.

Who sold ChromaDex stock? Who is selling ChromaDex stock?

ChromaDex's stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP, Tieton Capital Management LLC and Segall Bryant & Hamill LLC. View Insider Buying and Selling for ChromaDex.

Who bought ChromaDex stock? Who is buying ChromaDex stock?

ChromaDex's stock was purchased by a variety of institutional investors in the last quarter, including Thompson Davis & CO. Inc. and Granite Investment Partners LLC. Company insiders that have bought ChromaDex stock in the last two years include Frank L Jaksch Jr, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer, Stephen R Allen and Troy Allen Rhonemus. View Insider Buying and Selling for ChromaDex.

How do I buy ChromaDex stock?

Shares of ChromaDex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ChromaDex's stock price today?

One share of ChromaDex stock can currently be purchased for approximately $6.24.

How big of a company is ChromaDex?

ChromaDex has a market capitalization of $313.70 million and generates $26.81 million in revenue each year. The company earns $-2,920,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. ChromaDex employs 93 workers across the globe.

How can I contact ChromaDex?

ChromaDex's mailing address is 10005 Muirlands Blvd. Suite G, IRVINE CA, 92618. The company can be reached via phone at 949-419-0288 or via email at [email protected]


MarketBeat Community Rating for ChromaDex (CDXC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  162
MarketBeat's community ratings are surveys of what our community members think about ChromaDex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ChromaDex (NASDAQ:CDXC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$6.33$5.50$6.00
Price Target Upside: 4.48% upside47.29% upside36.14% upside119.78% upside

ChromaDex (NASDAQ:CDXC) Consensus Price Target History

Price Target History for ChromaDex (NASDAQ:CDXC)

ChromaDex (NASDAQ:CDXC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/27/2017HC WainwrightBoost Price TargetBuy$6.00 -> $8.00LowView Rating Details
9/25/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$7.00N/AView Rating Details
1/3/2017Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

ChromaDex (NASDAQ:CDXC) Earnings History and Estimates Chart

Earnings by Quarter for ChromaDex (NASDAQ:CDXC)

ChromaDex (NASDAQ CDXC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
8/10/2017Q2 2017$0.04($0.05)$11.00 million$5.31 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.01)($0.06)$5.60 million$5.64 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.03)$5.01 millionViewListenView Earnings Details
8/11/2016Q216$0.01$6.10 million$8.80 millionViewListenView Earnings Details
5/12/2016Q116$0.01$5.30 million$7.30 millionViewListenView Earnings Details
11/21/2013Q3 13($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

ChromaDex (NASDAQ:CDXC) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.15 EPS
Next Year EPS Consensus Estimate: $0.05 EPS

Dividends

Dividend History for ChromaDex (NASDAQ:CDXC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ChromaDex (NASDAQ CDXC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.59%
Institutional Ownership Percentage: 6.82%
Insider Trades by Quarter for ChromaDex (NASDAQ:CDXC)
Institutional Ownership by Quarter for ChromaDex (NASDAQ:CDXC)

ChromaDex (NASDAQ CDXC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/17/2017River Ventures Ltd ChampionMajor ShareholderBuy731,707$4.10$2,999,998.70View SEC Filing  
8/25/2017Stephen R AllenDirectorBuy2,000$3.31$6,620.00View SEC Filing  
8/18/2017Step Holdings Ltd PioneerMajor ShareholderBuy786,167$2.60$2,044,034.20View SEC Filing  
8/15/2017Robert N FriedInsiderBuy10,000$3.15$31,500.00View SEC Filing  
5/24/2017Step Holdings Ltd PioneerMajor ShareholderBuy2,521,526$2.60$6,555,967.60View SEC Filing  
5/19/2017Stephen R AllenDirectorBuy3,000$3.20$9,600.00View SEC Filing  
3/20/2017Stephen R AllenDirectorBuy2,000$2.81$5,620.00View SEC Filing  
12/12/2016Frank L Jaksch JrCEOBuy2,000$2.42$4,840.00View SEC Filing  
9/1/2016Frank L Jaksch JrCEOBuy1,500$3.32$4,980.00View SEC Filing  
9/1/2016Robert N FriedDirectorBuy15,000$3.39$50,850.00View SEC Filing  
6/20/2016Troy Allen RhonemusCOOBuy7,800$3.47$27,066.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ChromaDex (NASDAQ CDXC) News Headlines

Source:
DateHeadline
BRIEF-Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling StockholdersBRIEF-Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders
www.reuters.com - December 14 at 5:30 PM
Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function ... - NasdaqPublished Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function ... - Nasdaq
www.nasdaq.com - December 14 at 10:03 AM
Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart FailurePublished Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart Failure
finance.yahoo.com - December 14 at 10:03 AM
ChromaDex (CDXC) Says Nicotinamide Riboside Shown in Published Research to Improve Mitochondrial Energy ... - StreetInsider.comChromaDex (CDXC) Says Nicotinamide Riboside Shown in Published Research to Improve Mitochondrial Energy ... - StreetInsider.com
www.streetinsider.com - December 10 at 9:50 AM
Analyzing ChromaDex (CDXC) and The CompetitionAnalyzing ChromaDex (CDXC) and The Competition
www.americanbankingnews.com - December 9 at 7:18 PM
Nicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer’s Disease ResearchNicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer’s Disease Research
finance.yahoo.com - December 8 at 9:55 AM
ChromaDex (CDXC) Downgraded by ValuEngine to "Sell"ChromaDex (CDXC) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 3 at 7:58 PM
ChromaDex (CDXC) Lowered to Hold at Zacks Investment ResearchChromaDex (CDXC) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 29 at 6:04 PM
ChromaDex (CDXC) Raised to "Buy" at Zacks Investment ResearchChromaDex (CDXC) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 28 at 6:30 PM
Zacks: Analysts Set $6.50 Target Price for ChromaDex Corporation (CDXC)Zacks: Analysts Set $6.50 Target Price for ChromaDex Corporation (CDXC)
www.americanbankingnews.com - November 28 at 5:36 AM
ChromaDex Corporation (CDXC) Price Target Raised to $8.00ChromaDex Corporation (CDXC) Price Target Raised to $8.00
www.americanbankingnews.com - November 27 at 4:44 PM
 Analysts Set $6.50 Target Price for ChromaDex Corporation (CDXC) Analysts Set $6.50 Target Price for ChromaDex Corporation (CDXC)
www.americanbankingnews.com - November 21 at 7:33 PM
ChromaDex Corporation (CDXC) Major Shareholder Acquires $2,999,998.70 in StockChromaDex Corporation (CDXC) Major Shareholder Acquires $2,999,998.70 in Stock
www.americanbankingnews.com - November 21 at 1:33 PM
Head-To-Head Analysis: ChromaDex Corporation (CDXC) vs. Advaxis (ADXS)Head-To-Head Analysis: ChromaDex Corporation (CDXC) vs. Advaxis (ADXS)
www.americanbankingnews.com - November 17 at 3:34 AM
Investors Buy High Volume of ChromaDex Corporation Call Options (CDXC)Investors Buy High Volume of ChromaDex Corporation Call Options (CDXC)
www.americanbankingnews.com - November 16 at 2:06 AM
ChromaDex Corporation Sees Unusually Large Options Volume (CDXC)ChromaDex Corporation Sees Unusually Large Options Volume (CDXC)
www.americanbankingnews.com - November 16 at 2:06 AM
ChromaDexs (CDXC) CEO Frank Jaksch on Q1 2016 Results - Earnings Call TranscriptChromaDex's (CDXC) CEO Frank Jaksch on Q1 2016 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 6:13 PM
CHROMADEX CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsCHROMADEX CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - May 16 at 6:12 AM
Q1 2016 Chromadex Corp Earnings Release - Before Market OpenQ1 2016 Chromadex Corp Earnings Release - Before Market Open
biz.yahoo.com - May 12 at 7:07 AM
CHROMADEX CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsCHROMADEX CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - April 21 at 6:31 AM
FDA Panel Snubs CLVS, Big Gains For RPRX, PTIE To Face FDA AgainFDA Panel Snubs CLVS, Big Gains For RPRX, PTIE To Face FDA Again
www.rttnews.com - April 13 at 12:08 AM
CHROMADEX CORP. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, FiCHROMADEX CORP. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Fi
biz.yahoo.com - April 12 at 4:07 PM
CHROMADEX CORP. Files SEC form 10-K, Annual ReportCHROMADEX CORP. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 17 at 4:10 PM
Q4 2015 Chromadex Corp Earnings Release - After Market CloseQ4 2015 Chromadex Corp Earnings Release - After Market Close
biz.yahoo.com - March 17 at 7:07 AM
CHROMADEX CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritieCHROMADEX CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securitie
biz.yahoo.com - March 11 at 5:25 PM
ChromaDex Initiates Second Human Clinical Study On NIAGEN® -The Worlds First And Only Commercially Available Form Of Nicotinamide Riboside (NR)ChromaDex Initiates Second Human Clinical Study On NIAGEN® -The World's First And Only Commercially Available Form Of Nicotinamide Riboside (NR)
www.thestreet.com - March 11 at 10:16 AM
CHROMADEX CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsCHROMADEX CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - March 3 at 4:45 PM
CHROMADEX CORP. Files SEC form 8-K, Entry into a Material Definitive AgreementCHROMADEX CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - February 25 at 5:00 PM
CHROMADEX CORP. Files SEC form 10-Q, Quarterly ReportCHROMADEX CORP. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 12 at 5:39 PM

SEC Filings

ChromaDex (NASDAQ:CDXC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

ChromaDex (NASDAQ CDXC) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.